{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T18:47:11Z","timestamp":1785696431821,"version":"3.56.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder with a variable disease course presenting either as monophasic or non-monophasic (polycyclic or persistent) course. Identifying clinical and laboratory features at presentation predicting these trajectories may guide early therapeutic decisions. This study aimed to evaluate predictors of disease course in children with sJIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study of children with sJIA over 18\u2009years. Clinical features, laboratory parameters, treatment and disease outcomes were reviewed. Children with sJIA were classified as having monophasic, polycyclic or persistent disease based on clinical course. Logistic regression analysis, adjusted for age, gender and year of diagnosis, was performed to evaluate predictors of non-monophasic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty children with sJIA were included; median age at diagnosis was 8\u2009years (interquartile range 3.5\u201311) with median follow-up of 6\u2009years (interquartile range 3\u201310). Thirty-four (42.5%) were monophasic, 8 (10%) were polycyclic and 38 (47.5%) had a persistent course. Rash (83.8%) was the most common presenting feature, followed by arthritis (66.3%), while macrophage activation syndrome (MAS) occurred in 18.8%. Polyarthritis at presentation was independently associated with non-monophasic disease (odds ratio 12.68; 95% CI: 2.69, 59.90; p =\u20090.001). There was weak evidence to support an association between the clinical features and laboratory parameters, including MAS at presentation and disease trajectory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sJIA is heterogeneous and difficult to predict disease course at initial presentation. Polyarthritis at presentation was associated with increased risk of a non-monophasic disease course in this study population. Early identification of these high-risk children may support timely escalation of targeted biologic therapy and improved long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag366","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:55:20Z","timestamp":1783770920000},"source":"Crossref","is-referenced-by-count":0,"title":["Systemic juvenile idiopathic arthritis: Are there any predictors of disease course?"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-1643","authenticated-orcid":false,"given":"Ashwini","family":"Prithvi","sequence":"first","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-4328","authenticated-orcid":false,"given":"Chaitra","family":"Govardhan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2432-4328","authenticated-orcid":false,"given":"Bushra","family":"Aladaileh","sequence":"additional","affiliation":[{"name":"Paediatric Allergy, Immunology and Rheumatology Division, Queen Rania Children\u2019s Hospital, Jordanian Royal Medical Services , Amman,","place":["Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6804-008X","authenticated-orcid":false,"given":"Florence","family":"Martin","sequence":"additional","affiliation":[{"name":"MRC Integrative Epidemiology Unit, University of Bristol , Bristol,","place":["UK"]},{"name":"Population Health Sciences, University of Bristol , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2401","authenticated-orcid":false,"given":"Athimalaipet V","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children , Bristol,","place":["UK"]},{"name":"Translational Health Sciences, University of Bristol , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"2026080110062606100_keag366-B1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026080110062606100_keag366-B2","first-page":"491","article-title":"Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years","volume":"27","author":"Lomater","year":"2000","journal-title":"J Rheumatol"},{"key":"2026080110062606100_keag366-B3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.21774","article-title":"Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features","volume":"54","author":"Singh-Grewal","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026080110062606100_keag366-B4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12969-023-00886-9","article-title":"Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort","volume":"21","author":"Wallimann","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026080110062606100_keag366-B5","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2026080110062606100_keag366-B6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1586\/eci.12.49","article-title":"Tocilizumab for the treatment of systemic juvenile idiopathic arthritis","volume":"8","author":"Herlin","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"2026080110062606100_keag366-B7","first-page":"211","article-title":"Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis","volume":"19","author":"Modesto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2026080110062606100_keag366-B8","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/mr\/roae036","article-title":"Predictors of disease course in systemic juvenile idiopathic arthritis","volume":"34","author":"Kaplan","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026080110062606100_keag366-B9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/rheumatology\/keh710","article-title":"Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?","volume":"44","author":"Ramanan","year":"2005","journal-title":"Rheumatology"},{"key":"2026080110062606100_keag366-B10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026080110062606100_keag366-B11","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1007\/s10067-018-4297-6","article-title":"Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis","volume":"37","author":"Baris","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026080110062606100_keag366-B12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/art.41488","article-title":"Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a Phase IIIb\/IV open-label, randomized study","volume":"73","author":"Quartier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026080110062606100_keag366-B13","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080110062606100_keag366-B14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026080110062606100_keag366-B15","doi-asserted-by":"publisher","first-page":"1218312","DOI":"10.3389\/fped.2023.1218312","article-title":"Systemic juvenile idiopathic arthritis: the Great Ormond Street Hospital experience (2005-2021)","volume":"11","author":"Foley","year":"2023","journal-title":"Front Pediatr"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag366\/68760336\/keag366.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/8\/keag366\/68760336\/keag366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/8\/keag366\/68760336\/keag366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T18:21:54Z","timestamp":1785694914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag366\/8732685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag366","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,11]]},"article-number":"keag366"}}